Evidence map›Paper›PMID 29993282›Full record

ArticleEuropean journal of preventive cardiology2018

Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study.

Michél Strauss, Wayne Smith, Ruan Kruger, Wen Wei, Olga V Fedorova, Aletta E Schutte

Open access · greenAbstract read
In one paragraph

Article in European journal of preventive cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. The NaCurrent hypertension reports · 2019
    Review
  11. Observational
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Michél Strauss1 Hypertension in Africa Research Team (HART), North-West University, South Africa.
Wayne Smith1 Hypertension in Africa Research Team (HART), North-West University, South Africa.
Ruan Kruger1 Hypertension in Africa Research Team (HART), North-West University, South Africa.
Wen Wei3 National Institute on Aging, National Institutes of Health, USA.
Olga V Fedorova3 National Institute on Aging, National Institutes of Health, USA.
Aletta E Schutte1 Hypertension in Africa Research Team (HART), North-West University, South Africa.
North-West University · ZAInstitute on Aging · USNational Institutes of Health · US

Funding

Exploring the involvement of Na pump inhibitor marinobufagenin in the interactions between age-associated vascular and neurodegenerative processes in cognitive impairment and Alzheimer's diseaseZIAAG000846 · NIA · NATIONAL INSTITUTE ON AGING · PI FEDOROVA, OLGA V · 2016 to 2025
$17.7M
Sodium pump ligands in blood pressure regulation and profibrotic signaling in hypertension, chronic kidney disease and aging in males and femalesZIAAG000609 · NIA · NATIONAL INSTITUTE ON AGING · PI FEDOROVA, OLGA V · 2009 to 2025
$17.3M
Marinobufagenin as a therapeutic targetZIAAG000869 · NIA · NATIONAL INSTITUTE ON AGING · PI LAKATTA, EDWARD · 2009 to 2025
$14.8M
SODIUM PUMP INHIBITORS IN CARDIOVASCULAR CONTROLZ01AG000609 · NIA · NATIONAL INSTITUTE ON AGING · PI BAGROV, ALEXEI Y · 1993 to 2008
$1.2M
Intramural NIH HHS Z01 AG000609Intramural NIH HHS Z99 AG999999Medical Research Council MC_PC_16095
6 · The paper itself

Abstract

Background The endogenous steroidal inhibitor of sodium-potassium-dependent adenosine triphosphate and natriuretic hormone, marinobufagenin, plays a physiological role in ionic homeostasis. Animal models suggest that elevated marinobufagenin adversely associates with cardiac and renal, structural and functional alterations. It remains uncertain whether marinobufagenin relates to the early stages of target organ damage development, especially in young adults without cardiovascular disease. We therefore explored whether elevated 24-hour urinary marinobufagenin excretion was related to indices of subclinical target organ damage in young healthy adults. Design This cross-sectional study included 711 participants from the African-PREDICT study (black 51%, men 42%, 24.8 ± 3.02 years). Methods We assessed cardiac geometry and function by two-dimensional echocardiography and pulse wave Doppler imaging. 24-Hour urinary marinobufagenin and sodium excretion were measured, and the estimated glomerular filtration rate determined. Results Across marinobufagenin excretion quartiles, left ventricular mass ( P < 0.001), end diastolic volume ( P < 0.001), stroke volume ( P = 0.004) and sodium excretion ( P < 0.001) were higher within the fourth compared with the first quartile. Partial regression analyses indicated that left ventricular mass ( r = 0.08, P = 0.043), end diastolic volume ( r = 0.10, P = 0.010) and stroke volume ( r = 0.09, P = 0.022) were positively related to marinobufagenin excretion. In multivariate-adjusted regression analysis, left ventricular mass associated positively with marinobufagenin excretion only in the highest marinobufagenin excretion quartile (adjusted R

Indexed as

Ventricular Function, LeftVentricular RemodelingAdultAsymptomatic DiseasesBiomarkersBufanolidesCross-Sectional StudiesEchocardiography, DopplerFemaleHumansHypertrophy, Left VentricularMalePredictive Value of TestsPrognosisProspective StudiesRisk AssessmentBiomarkersBufanolidesmarinobufageninApparently healthyleft ventricular mass indexmarinobufageninyoung adults

Identifiers

PMID29993282
PMCPMC6209078
OpenAlexW2834782578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.